Finanzas de CNS Pharmaceuticals Inc (CNSP)CNSPCNS Pharmaceuticals Inc

Evaluating the bottom line, CNS Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -106.62%, provide a clear picture of how effectively CNSP converts its operational activities into shareholder value.

In the context of the broader market, CNSP competes directly with industry leaders such as ALZN and SNGX. With a market capitalization of $8.74M, it holds a leading position in the sector. When comparing efficiency, CNSP's gross margin of N/A stands against ALZN's N/A and SNGX's N/A. Such benchmarking helps identify whether CNS Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

CNS Pharmaceuticals has faced significant financial challenges, with a net loss of $4.94 million in Q1 2026 and a negative EPS of -0.38. The company has also shown a declining trend in net income over the past quarters, indicating ongoing financial strain.